How This Evidence Evolved
BPH Surgical Options
From TURP to Minimally Invasive Procedures
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Functional outcomes and treatment-related adverse events
AUA symptom score at 3 years: HoLEP 2.7 vs TURP 3.3 (p=0.17); Qmax 29.0 vs 27.5 ml/s (p=0.41); reoperation 7.2% vs 6.6% (p=1.0)
AUA symptom score at 5 years: HoLEP 3.0 vs open prostatectomy 3.0 (p=0.98); Qmax 24.4 ml/s in both (p=0.97); reoperation 5% vs 6.7% (p=1.0)
Follow-up studies, subgroup analyses, and real-world validation
AUASI reduction at 3 months: urethral lift 11.1 vs sham 5.9 points (p=0.003)
IPSS reduction at 6 months: Aquablation vs TURP (noninferior, p<0.0001); Clavien-Dindo safety end point 26% vs 42% (p=0.0149)
IPSS reduction at 3 months: Rezum 11.2 vs sham 4.3 points (p<0.0001)
IPSS at 3 months: 23.2±6.3 at baseline vs 6.7±5.1 (P<0.001); Clavien-Dindo grade 2 or higher or persistent grade 1 events at 3 months 45.5% (goal <65%, P<0.001)
Current standard of care and ongoing research directions
Landmark Trials in This Story
Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients.
Mortality and immediate postoperative morbidity after TURP (3,885 patients, 13 institutions): 0.2% and 18%
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement
Functional outcomes and treatment-related adverse events
Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial.
AUA symptom score at 3 years: HoLEP 2.7 vs TURP 3.3 (p=0.17); Qmax 29.0 vs 27.5 ml/s (p=0.41); reoperation 7.2% vs 6.6% (p=1.0)
Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial.
AUA symptom score at 5 years: HoLEP 3.0 vs open prostatectomy 3.0 (p=0.98); Qmax 24.4 ml/s in both (p=0.97); reoperation 5% vs 6.7% (p=1.0)
The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study
AUASI reduction at 3 months: urethral lift 11.1 vs sham 5.9 points (p=0.003)
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
IPSS reduction at 6 months: Aquablation vs TURP (noninferior, p<0.0001); Clavien-Dindo safety end point 26% vs 42% (p=0.0149)
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
IPSS reduction at 3 months: Rezum 11.2 vs sham 4.3 points (p<0.0001)
Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial.
IPSS at 3 months: 23.2±6.3 at baseline vs 6.7±5.1 (P<0.001); Clavien-Dindo grade 2 or higher or persistent grade 1 events at 3 months 45.5% (goal <65%, P<0.001)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.